Quantum Biopharma (QNTM) Cash from Investing Activities (2019 - 2026)

Quantum Biopharma has reported Cash from Investing Activities for 7 years, with the latest figure at -$2.9 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 114.28% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 million (down 23.45% YoY) and the FY2025 annual result came in at -$2.0 million, down 29.86% from the prior year.
• Cash from Investing Activities slipped to -$2.9 million in Q1 2026 per QNTM's latest filing, from $350650.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $11.9 million in Q4 2022 and troughed at -$3.5 million in Q3 2024.
• A 4-year average of $495684.4 and a median of -$22140.0 in 2024 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 111.79% in 2025, down 5998.5% in 2025.
• Over 4 years, Cash from Investing Activities stood at $11.9 million in 2022, then tumbled by 89.55% to $1.2 million in 2024, then tumbled by 71.81% to $350650.0 in 2025, then plunged by 925.11% to -$2.9 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2.9 million, $350650.0, and $408419.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.